Fasting Insulin Has Limited Clinical Utility in Diabetes Management
Fasting insulin measurement is not routinely recommended for the diagnosis or management of diabetes in clinical practice. The established diagnostic criteria rely on fasting glucose, HbA1c, or oral glucose tolerance testing—not insulin levels 1.
Why Fasting Insulin Is Not Standard Practice
Diagnostic Limitations
The 2023 guidelines explicitly state that routine testing for insulin or proinsulin is not recommended in most people with diabetes or at risk for diabetes 2. These assays are considered useful primarily for research purposes, not clinical care.
The diagnosis of diabetes is based on:
- Fasting blood glucose ≥126 mg/dL on two occasions
- HbA1c ≥6.5% on two occasions
- Random glucose ≥200 mg/dL with symptoms
- 2-hour OGTT glucose ≥200 mg/dL 1
Insulin levels play no role in these diagnostic criteria.
When Fasting Insulin May Be Useful
There are only three specific clinical scenarios where insulin or C-peptide measurement has value 2:
- Differentiating Type 1 from Type 2 diabetes in ambiguous cases (e.g., patients with type 2 phenotype presenting in ketoacidosis)—use C-peptide, not insulin
- Investigating hypoglycemia to rule out insulinoma or surreptitious insulin administration
- Insurance requirements for insulin pump coverage (fasting C-peptide when glucose ≤220 mg/dL)
Research Context vs. Clinical Practice
While research shows fasting insulin can predict diabetes risk 3 and correlates with insulin resistance 4, this does not translate to routine clinical utility. The correlation between fasting insulin and insulin resistance weakens substantially in patients with impaired glucose tolerance or established diabetes 4.
One study suggested fasting insulin >9.0 μIU/mL could identify prediabetes with 80% accuracy 5, but this has not been incorporated into clinical guidelines because:
- It adds no actionable information beyond fasting glucose and HbA1c
- Treatment decisions are based on glucose levels, not insulin levels
- Cost-effectiveness is questionable
Common Pitfall to Avoid
Do not order fasting insulin to "assess insulin resistance" in routine diabetes care. Clinical assessment (BMI, waist circumference, acanthosis nigricans) combined with glucose/HbA1c provides sufficient information for treatment decisions 2. The guidelines specifically note that measuring insulin resistance through insulin levels has no advantage over physical examination findings.
What Actually Matters for Diabetes Management
Focus on monitoring that directly impacts treatment decisions 6, 7:
- Self-monitoring of blood glucose (SMBG) for insulin-treated patients
- HbA1c every 3 months until at goal, then every 6 months
- Fasting glucose to titrate basal insulin doses
- Continuous glucose monitoring (CGM) for intensive insulin regimens
These measurements directly guide medication adjustments, whereas fasting insulin does not.
Bottom Line
Fasting insulin measurement has no established role in routine diabetes diagnosis, screening, or management according to current guidelines 1, 2. Save it for the rare situations where distinguishing diabetes type or investigating hypoglycemia is necessary—and even then, C-peptide is often the preferred test.